Выходит 6 номеров в год
ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502
Indexed in
The Development of Monoclonal Antibodies for the Therapy of Cancer
Краткое описание
Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.
-
Davol Pamela A., Smith Janelle A., Kouttab Nicola, Elfenbein Gerald J., Lum Lawrence G., Anti-CD3 × Anti-HER2 Bispecific Antibody Effectively Redirects Armed T Cells to Inhibit Tumor Development and Growth in Hormone-Refractory Prostate Cancer–Bearing Severe Combined Immunodeficient Beige Mice, Clinical Prostate Cancer, 3, 2, 2004. Crossref
-
Neyt Mattias, Cost Considerations for Monoclonal Antibody-Targeted Therapy in Cancer, American Journal of Cancer, 5, 1, 2006. Crossref
-
Goldstein D., Lambert G., Puisieux Fr., Benita S., Les systèmes colloïdaux de délivrance de médicaments ont-ils aidé à répondre aux espérances thérapeutiques des découvertes de biotechnologie ?, Annales Pharmaceutiques Françaises, 63, 1, 2005. Crossref
-
Quan Maureen, Carter Paul, The Rise of Antibodies as Therapeutics, in IgE and Anti-IgE Therapy in Asthma and Allergic Disease, 20023077, 2002. Crossref
-
Oh Phil, Li Yan, Yu Jingyi, Durr Eberhard, Krasinska Karolina M., Carver Lucy A., Testa Jacqueline E., Schnitzer Jan E., Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy, Nature, 429, 6992, 2004. Crossref
-
Qu C F, Li Y, Song Y J, Rizvi S M A, Raja C, Zhang D, Samra J, Smith R, Perkins A C, Apostolidis C, Allen B J, MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate, British Journal of Cancer, 91, 12, 2004. Crossref
-
Sen Manjula, Wankowski Dawn M., Garlie Nina K., Siebenlist Ruth E., Van Epps Dennis, LeFever Ann V., Lum Lawrence G., Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+Tumors, Journal of Hematotherapy & Stem Cell Research, 10, 2, 2001. Crossref
-
Khawli Leslie A., Biela Barbara H., Hu Peisheng, Epstein Alan L., Stable, Genetically Engineered F(ab′)2Fragments of Chimeric TNT-3 Expressed in Mammalian Cells, Hybridoma and Hybridomics, 21, 1, 2002. Crossref
-
Newsome Barrett W., Ernstoff Marc S., The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?, British Journal of Clinical Pharmacology, 66, 1, 2008. Crossref
-
DeNardo Sally J, Kroger Linda A, DeNardo Gerald L, A new era for radiolabeled antibodies in cancer?, Current Opinion in Immunology, 11, 5, 1999. Crossref
-
Goldstein Danny, Nassar Taher, Lambert Gregory, Kadouche Jean, Benita Simon, The design and evaluation of a novel targeted drug delivery system using cationic emulsion–antibody conjugates, Journal of Controlled Release, 108, 2-3, 2005. Crossref
-
Popkov M, Sidrac-Ghali S, Lusignan Y, Lemieux S, Mandeville R, Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9, European Journal of Cancer, 37, 18, 2001. Crossref
-
Madhusudan Srinivasan, Ganesan Trivadi S., Tyrosine kinase inhibitors in cancer therapy, Clinical Biochemistry, 37, 7, 2004. Crossref
-
Bézian Jean-Henri, Moynet Daniel, Comeau Sylvie, Chagnaud Jean-Luc, L'ingénierie des anticorps et ses applications, Revue Française des Laboratoires, 2000, 327, 2000. Crossref
-
Borrebaeck Carl A.K, Antibodies in diagnostics – from immunoassays to protein chips, Immunology Today, 21, 8, 2000. Crossref
-
Zwick Esther, Bange Johannes, Ullrich Axel, Receptor tyrosine kinases as targets for anticancer drugs, Trends in Molecular Medicine, 8, 1, 2002. Crossref
-
Hudson Peter J, Kortt Alexander A, High avidity scFv multimers; diabodies and triabodies, Journal of Immunological Methods, 231, 1-2, 1999. Crossref
-
Glennie Martin J, Johnson Peter W.M, Clinical trials of antibody therapy, Immunology Today, 21, 8, 2000. Crossref
-
Mitra Siddhartha, Li Gordon, Harsh Griffith R., Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas, Neurosurgery Clinics of North America, 21, 1, 2010. Crossref
-
Kleinschmidt Martin, Rudolph Rainer, Lilie Hauke, Design of a Modular Immunotoxin Connected by Polyionic Adapter Peptides, Journal of Molecular Biology, 327, 2, 2003. Crossref
-
Tamilvanan Shunmugaperumal, Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body, International Journal of Pharmaceutics, 381, 1, 2009. Crossref
-
Hudson Peter J, Recombinant antibody constructs in cancer therapy, Current Opinion in Immunology, 11, 5, 1999. Crossref
-
Zola Heddy, Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies, Expert Opinion on Biological Therapy, 1, 3, 2001. Crossref
-
Binyamin Liat, Borghaei Hossein, Weiner Louis M., Cancer therapy with engineered monoclonal antibodies, Update on Cancer Therapeutics, 1, 2, 2006. Crossref
-
Buolamwini John K, Novel anticancer drug discovery, Current Opinion in Chemical Biology, 3, 4, 1999. Crossref
-
Tamilvanan S., Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems, Progress in Lipid Research, 43, 6, 2004. Crossref
-
Tejuca M, Dı́az I, Figueredo R, Roque L, Pazos F, Martı́nez D, Iznaga-Escobar N, Pérez R, Alvarez C, Lanio M.E, Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line, International Immunopharmacology, 4, 6, 2004. Crossref
-
Todorovska Aneta, Roovers Rob C., Dolezal Olan, Kortt Alexander A., Hoogenboom Hennie R., Hudson Peter J., Design and application of diabodies, triabodies and tetrabodies for cancer targeting, Journal of Immunological Methods, 248, 1-2, 2001. Crossref
-
Soper Steven A., Brown Kathlynn, Ellington Andrew, Frazier Bruno, Garcia-Manero Guillermo, Gau Vincent, Gutman Steven I., Hayes Daniel F., Korte Brenda, Landers James L., Larson Dale, Ligler Frances, Majumdar Arun, Mascini Marco, Nolte David, Rosenzweig Zeev, Wang Joseph, Wilson David, Point-of-care biosensor systems for cancer diagnostics/prognostics, Biosensors and Bioelectronics, 21, 10, 2006. Crossref
-
Revets Hilde, De Baetselier Patrick, Muyldermans Serge, Nanobodies as novel agents for cancer therapy, Expert Opinion on Biological Therapy, 5, 1, 2005. Crossref
-
Smith Jill P, Verderame Michael F, Ballard Elizabeth N, Zagon Ian S, Functional significance of gastrin gene expression in human cancer cells, Regulatory Peptides, 117, 3, 2004. Crossref
-
Kratz F, Warnecke A, Riebeseel K, Rodrigues P, Anticancer Drug Conjugates with Macromolecular Carriers, in Polymeric Biomaterials, Revised and Expanded, 2001. Crossref
-
Lv Xinxin, Zhang Jian, Xu Rui, Dong Yuguo, Sun Aiyou, Shen Yaling, Wei Dongzhi, Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells, Applied Microbiology and Biotechnology, 100, 14, 2016. Crossref
-
Roth Robert I., Magic Bullets Finally Find Their Mark, Journal of the American Pharmaceutical Association (1996), 41, 3, 2001. Crossref
-
Augustine Samuel C., Norenberg Jeffrey P., Colcher David M., Vose Julie M., Gobar Lisa S., Dukat Valorie J., Hohenstein Maribeth A., Rutar Frank J., Jacobson David A., Tempero Margaret A., Combination Therapy for Non-Hodgkin’s Lymphoma: An Opportunity for Pharmaceutical Care in a Specialty Practice, Journal of the American Pharmaceutical Association (1996), 42, 1, 2002. Crossref
-
Cortez-Retamozo Virna, Lauwereys Marc, Hassanzadeh Gh. Gholamreza, Gobert Martine, Conrath Katja, Muyldermans Serge, De Baetselier Patrick, Revets Hilde, Efficient tumor targeting by single-domain antibody fragments of camels, International Journal of Cancer, 98, 3, 2002. Crossref
-
Beum Paul V., Singh Jaswant, Burdick Michael, Hollingsworth Michael A., Cheng Pi-Wan, Expression of Core 2 β-1,6-N-Acetylglucosaminyltransferase in a Human Pancreatic Cancer Cell Line Results in Altered Expression of MUC1 Tumor-associated Epitopes, Journal of Biological Chemistry, 274, 35, 1999. Crossref
-
Shunmugaperumal Tamilvanan, Thenrajan Raja Sekharan, Sharma Ruchi, Multifunctional nanosized emulsions for theragnosis of life threatening diseases, in Nanostructures for Drug Delivery, 2017. Crossref
-
Smallshaw Joan E., Ghetie Victor, Rizo Jose, Fulmer John R., Trahan Linda L., Ghetie Maria-Ana, Vitetta Ellen S., Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice, Nature Biotechnology, 21, 4, 2003. Crossref
-
Micheel Burkhard, Monoklonale Antikörper, in Grundlagen der Molekularen Medizin, 2003. Crossref
-
Smallshaw Joan E., Vitetta Ellen S., Ricin Vaccine Development, in Ricin and Shiga Toxins, 357, 2011. Crossref
-
Behrsing Olaf, Micheel Burkhard, Monoklonale Antikörper: Grundlagen und ihre Bedeutung in Diagnostik und Therapie, in Grundlagen der Molekularen Medizin, 2008. Crossref
-
Ghetie Victor, Ward E. Sally, Vitetta Ellen S., Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans, in Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2004. Crossref
-
Murray A., Denton G., Price M. R., Perkins A. C., Antibody targeted therapy: delivery of radionuclides, toxins and drugs, in Cancer Immunology, 2001. Crossref
-
Borghaei Hossein, Binyamin Liat, Astsaturov Igor, Weiner Louis M., Antibody Therapy of Cancer, in Molecular Targeting in Oncology, 2008. Crossref
-
Madhusudan Srinivasan, Ganesan Trivadi S., Tyrosine Kinase Inhibitors and Cancer Therapy, in Targeted Interference with Signal Transduction Events, 172, 2007. Crossref
-
Tassone Pierfrancesco, Goldmacher Victor S., Neri Paola, Gozzini Antonella, Shammas Masood A., Whiteman Kathleen R., Hylander-Gans Linda L., Carrasco Daniel R., Hideshima Teru, Shringarpure Reshma, Shi Jialan, Allam Charles K., Wijdenes John, Venuta Salvatore, Munshi Nikhil C., Anderson Kenneth C., Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells, Blood, 104, 12, 2004. Crossref
-
Tumor Immunity, in Immunology, Immunopathology, and Immunity, 2001. Crossref
-
Chen Jia, Yin Sheng, Wu Yongjian, Ouyang Jun, Development of a Native Nanoelectrospray Mass Spectrometry Method for Determination of the Drug-to-Antibody Ratio of Antibody–Drug Conjugates, Analytical Chemistry, 85, 3, 2013. Crossref
-
West Anthony P., Bjorkman Pamela J., Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor,, Biochemistry, 39, 32, 2000. Crossref
-
Carter Paul, Improving the efficacy of antibody-based cancer therapies, Nature Reviews Cancer, 1, 2, 2001. Crossref
-
Tassone Pierfrancesco, Gozzini Antonella, Goldmacher Victor, Shammas Masood A., Whiteman Kathleen R., Carrasco Daniel R., Li Cheng, Allam Charles K., Venuta Salvatore, Anderson Kenneth C., Munshi Nikhil C., In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901- N 2′-Deacetyl- N 2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells, Cancer Research, 64, 13, 2004. Crossref
-
Valadon Philippe, Garnett Jeff D., Testa Jacqueline E., Bauerle Marc, Oh Phil, Schnitzer Jan E., Screening phage display libraries for organ-specific vascular immunotargeting in vivo , Proceedings of the National Academy of Sciences, 103, 2, 2006. Crossref
-
Brekke Ole Henrik, Sandlie Inger, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nature Reviews Drug Discovery, 2, 1, 2003. Crossref